



Company
Therabiopharma Inc.

Presenter
Atsuhiro
Kishimoto





CMG(curcumin monoglucuronide) indicates strong evidence to be a solution against Drug Resistance(DR) which presents a serious challenge to the efficiency of current cancer treatments

CMG(curcumin monoglucuronide) was developed as prodrug of curcumin and injectable form which can deliver 10,000times higher free form of curcumin in the blood stream than oral intake of standard curcumin.



CMG effectively suppresses the double mutated Colon cancer both in vitro




HCT116	A	B	C
KRAS	wild	mutation	mutation
p53	wild	wild	mutation

* : p < 0.01

in vivo

using the double mutated HCT116



* : p < 0.05

CMG (curcumin monoglucuronide) could reduce the growth of the double mutated colon cancer cell (HCT116: KRAS and P53 both mutated) which is strongly resistant for the cancer drugs such as Oxaliplatin in vivo. However, CMG alone could suppress the tumor and CMG with Oxaliplatin reverse Oxaliplatin efficacy against this tough cancer.